Legato Capital Management’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$862K Sell
62,633
-7,701
-11% -$114K 0.08% 393
2026
Q2
$1.12M Buy
70,334
+2,133
+3% +$34.3K 0.09% 315
2026
Q1
$897K Sell
68,201
-964
-1% -$14.5K 0.08% 320
2025
Q4
$1.07M Buy
69,165
+6,120
+10% +$81.8K 0.09% 340
2025
Q3
$650K Buy
63,045
+41,323
+190% +$390K 0.07% 404
2025
Q2
$242K Sell
21,722
-19,385
-47% -$242K 0.03% 508
2025
Q1
$505K Buy
+41,107
New +$515K 0.07% 422

Other funds holding NPCE

Legato Capital Management's NPCE Position: Q3 2026 in Review

Legato Capital Management reduced its Neuropace (NPCE) stake by 11% in Q3 2026, selling an estimated $114K and leaving 62,633 shares worth $862K. The position accounts for 0.08% of the portfolio, ranked #393.

Legato Capital Management first reported a position in NPCE in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.12M in Q2 2026. 105 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Legato Capital Management held 62,633 shares of Neuropace worth $862K as of Q3 2026.
  • Legato Capital Management sold 7,701 Neuropace shares in Q3 2026, an estimated $114K.
  • Neuropace made up 0.08% of Legato Capital Management's portfolio in Q3 2026, its #393 holding.
  • Legato Capital Management first reported a position in Neuropace in Q1 2025 and has held it in 7 quarters since.
  • Legato Capital Management's Neuropace position peaked at $1.12M in Q2 2026.
  • 105 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.